Development of new diabetes treatment to commence local trials.
BHR Pharmaceuticals based in Nuneaton are taking forward the development of a piece of technology known as FREMS for the management and treatment of diabetic wounds and peripheral neuropathies. The FREMS (Frequency Rhythmic Electrical Modulation System) device uses modulated frequency pulses to improve the supply of oxygen to nerve cells with the aim of reducing pain. Using specialist NHS staff BHR will undertake pilot clinical trials at the George Eliot Hospital in Nuneaton in order to generate evidence to push for further multi centre trials across the NHS and ultimately see the technology be adopted for treating diabetic neuropathies. If successful the use of FREMS could help reduce the financial burden the NHS experiences dealing with diabetic conditions and also provide patients with a non-invasive approach that helps provide pain relief without the need for drug treatment and prevent further debilitating illnesses associated with diabetes.
Bharat Vadukul, Director, BHR said: "The main treatments for painful diabetic neuropathy remain management of the underlying diabetes and drugs for the relief of pain. Despite the significant individual and social burden associated with diabetic neuropathy, its treatment remains unsatisfactory."
"Many therapies have been the subject of clinical trials for diabetic neuropathy and painful diabetic neuropathy. However, there are currently no FDA-approved therapies for diabetic neuropathy so our aim is to work to that and provide a treatment that is clinically proved and works."
Richard Middleton, Innovation Development Officer, Coventry City Council said: "The work BHR are doing could bring about the introduction of an exciting new emerging medical technology to the NHS that could bring cost savings and better outcomes for patients.
"Our grant funding will help BHR undertake pilot clinical trials in Coventry & Warwickshire that should provide further evidence to support the case for the NHS to adopt the technology. The results of the trials should generate interest from specialists in the clinical community."
The Coventry & Warwickshire Innovation Programme supports local SMEs to develop innovative products and services which are new to the market. If you are interested in the programme please email us at: firstname.lastname@example.org.